Dr. Albert A. Samadi, MD

Dr. Samadi practices at Facey Medical Group - Valencia Specialty & Women's Center in Valencia, California.

Dr. Samadi's NPI, 1619952637, was assigned on December 13, 2005. Dr. Samadi graduated from SUNY Downstate Health Sciences University in 1995. Dr. Samadi holds California license A96238.

Dr. Samadi's primary practice is Facey Medical Group - Valencia Specialty & Women's Center, at 23803 McBean Parkway, Valencia, CA 91355. The practice phone is (818) 869-7034.

Dr. Samadi's primary practice is Facey Medical Group - Valencia Specialty & Women's Center in Valencia, California. Dr. Samadi is also affiliated with Henry Mayo Newhall Hospital. The medical group on file is Facey Medical Group. Dmand AI also links Dr. Samadi to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Samadi practices, 4 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Samadi's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dmand AI has Dr. Samadi's licenses on file in 2 states: California and New York.

Dmand AI lists bladder disease, enlarged prostate, enlarged prostate transurethral surgery (TURP), erectile dysfunction, kidney cysts, kidney removal surgery, kidney stone disease and pelvic prolapse among the conditions Dr. Samadi treats.

CMS data shows 602 Medicare services from Dr. Samadi across 12 procedure codes in 2024, for 220 Medicare patients. Medicare paid $55,428 for them.

CMS counts 220 Medicare patients who saw Dr. Samadi in 2024. The largest group is 65 to 74, with 97 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 26% are also on Medicaid. Their average risk score is 1.75, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Samadi's median patient age at 70, with 21% women.

In 2024, Dr. Samadi wrote 963 Medicare Part D claims for 303 patients. 95% of them were for generic drugs. CMS names the drug for 861 of them, across 16 drugs with 11 or more claims each, at $50,579 in total drug cost. In 2023, CMS named 732 claims across 12 drugs.

Dr. Samadi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Samadi as offering telehealth. CMS counts 12 procedures of prostate resection by Dr. Samadi, more than 63% of the clinicians it reports for that procedure.

Dmand AI links 9 papers to Dr. Samadi. The most frequent topics are Agaricales, Laser Therapy and Prostatic Hyperplasia. Dr. Samadi has published most often in J Endourol. Dr. Samadi's most frequent co-authors are Scott David Davidson, MD, Samuel A. Amukele, MD and Shahrad Aynehchi, MD.

CMS Open Payments shows 73 general payments to Dr. Samadi from 26 drug and device companies from 2016 to 2025. Travel and lodging make up the largest share, 54% of the total. Boston Scientific Corporation paid the most, $1,368.

Dmand AI lists 1 award for Dr. Samadi, most recently CMS Stage 1 2012 in 2012.

Dr. Samadi graduated from SUNY Downstate Health Sciences University in 1995.

Dr. Samadi is in network with 11 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.